KDR and Miyoshi myopathy: Nevertheless, pazopanib did not show any therapeutic effect in MM patients enrolled in a phase II trial despite the suitable pharmacokinetic and evidence of pharmacodynamic effects on VEGFR inhibition such as depigmentation and hypertension [64].